Idiopathic pulmonary fibrosis digest - 2021

Idiopathic pulmonary fibrosis digest - 2021

Vicore Pharma and Alex Therapeutics to develop VP04 with Alex DTx Platform for cognitive behavioral therapy

VP04 (Alex DTx Platform) – Vicore Pharma/ Alex Therapeutics

  • Vicore Pharma signed an agreement with Alex Therapeutics AB for the development and clinical validation of an AI-powered digital therapeutic (DTx) built on the “Alex DTx Platform”
  • The agreement with Alex Therapeutics marks the initiation of a new clinical program for Vicore (VP04) – the joint development and commercialization of a clinically validated digital therapeutic (DTx) will provide cognitive behavioral therapy (CBT) for patients suffering from IPF
  • Under the agreement, Vicore will own all rights to VP04 in exchange for an upfront payment to Alex Therapeutics of 8.1 MSEK plus potential milestone payments and royalties on sales
  • Vicore and Alex Therapeutics expect to begin the clinical trial of VP04 in 2022 (For full story click here)

Alex DTx Platform to provide personalized cognitive behavioral therapy for the treatment of depression and anxiety associated with IPF

Share this

Facebook
fb-share-icon
Twitter
Tweet
LinkedIn
Share

CI Scientists Commentary:

  • IPF being a chronic illness will likely exert a dramatic impact on patients’ QOL
  • Anxiety occurs in approximately two-thirds of patients with IPF. Studies revealed the prevalence of depression in patients with IPF ranged from 24.3 to 49.2%
  • Mental health issues in IPF are often ignored
  • To address this issue, Vicore Pharma partnered with Alex Therapeutics aimed to create a mobile app that could help improve the mental health of patients with IPF
  • Vicore may evaluate this app in combination with its investigational drugs for IPF, VP01 (Phase 1), and VP02 (Preclinical)

– Dr. Kowndinya, CI Scientists

Home